Adynxx drug failed in PhII but it’s going into PhIII anyway; Deerfield leads $50M raise for Sollis

→ San Francisco-based Adynxx says that their Phase II study for a new non-opioid pain drug failed — but they’re going into Phase III in any case. Investigators hunted up patients based on the Pain Catastrophizing Scale, failing to see a statistical benefit in the post-surgical group for brivoligide (AYX1) over a placebo. They recruited 210 patients. The biotech, however, did find the results it was looking for in a group of patients with high PCS numbers, and that’s where they’ll be focusing in Phase III. That strategy of pushing into Phase III after a failed Phase II has proven to be a particularly risky approach to drug development, but that isn’t stopping Adynxx.

Andrew ElBardissi

Deerfield has shouldered the lion’s share of a $50 million investment in Columbus, OH-based Sollis Therapeutics. The biotech is working on a non-opioid, non-steroid pain therapy. “Sollis’ innovative treatment has the potential to provide immediate pain relief and long-term efficacy for millions of patients suffering from sciatica and other neuropathic pain conditions,” said Deerfield’s Andrew ElBardissi. Sollis is run by Gregory Fiore, the former CMO at The Medicines Co.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->